115 related articles for article (PubMed ID: 18407955)
1. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Mrozek E; Kolesar J; Young D; Allen J; Villalona-Calero M; Shapiro CL
Ann Oncol; 2008 Aug; 19(8):1417-1422. PubMed ID: 18407955
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Xu Y; Kolesar JM; Schaaf LJ; Drengler R; Duan W; Otterson G; Shapiro C; Kuhn J; Villalona-Calero MA
Cancer Chemother Pharmacol; 2009 May; 63(6):1073-82. PubMed ID: 18795290
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Yamao T; Shirao K; Matsumura Y; Muro K; Yamada Y; Goto M; Chin K; Shimada Y
Ann Oncol; 2001 Dec; 12(12):1729-35. PubMed ID: 11843251
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
Giuliani F; Molica S; Maiello E; Battaglia C; Gebbia V; Di Bisceglie M; Vinciarelli G; Gebbia N; Colucci G;
Am J Clin Oncol; 2005 Dec; 28(6):581-5. PubMed ID: 16317268
[TBL] [Abstract][Full Text] [Related]
6. Rationale for mitomycin and irinotecan use in advanced breast cancer.
Xu Y; Shapiro CL
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):25-8. PubMed ID: 12800602
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
Segar JM; Reed D; Stopeck A; Livingston RB; Chalasani P
Oncologist; 2019 Dec; 24(12):1512-e1267. PubMed ID: 31383812
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Bamias A; Papamichael D; Syrigos K; Pavlidis N
J Chemother; 2003 Jun; 15(3):275-81. PubMed ID: 12868555
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin C and capecitabine combination (MiXe) in heavily pretreated metastatic breast cancer patients. A dose-finding study.
Maisano R; Caristi N; Mare M; Mafodda A; Carboni R; Montalto E; Iorfida M; Nardi M
Anticancer Res; 2005; 25(6C):4513-7. PubMed ID: 16334135
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
[TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of irinotecan combined with mitomycin-C and 5-fluorouracil for gynecological malignancies: the JGOG study.
Kokawa K; Umesaki N; Yamamoto K; Takizawa K; Konishi I; Hasegawa K;
Anticancer Res; 2008; 28(5B):2933-9. PubMed ID: 19031936
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
[TBL] [Abstract][Full Text] [Related]
15. Mitomycin as a modulator of irinotecan anticancer activity.
Villalona-Calero MA; Kolesar JM
Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):21-5. PubMed ID: 12199629
[TBL] [Abstract][Full Text] [Related]
16. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
[TBL] [Abstract][Full Text] [Related]
17. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.
Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L
Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer.
Gil-Delgado MA; Antoine EC; Guinet F; Bassot V; Grapin JP; Benhammonda A; Adam R; Castaing D; Bismuth H; Khayat D
Am J Clin Oncol; 2001 Jun; 24(3):251-4. PubMed ID: 11404495
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
Yamada Y; Shirao K; Hyodo I; Arai Y; Denda T; Ambo T; Ohtsu A
Cancer Chemother Pharmacol; 2003 Aug; 52(2):125-30. PubMed ID: 12783200
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer.
Aoki Y; Kurata H; Watanabe M; Fujita K; Tanaka K
Am J Clin Oncol; 2004 Oct; 27(5):461-4. PubMed ID: 15596911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
